Oncolytic Adenovirus H101 in Combination with Vinorelbine/cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer

ZHOU Cai-cun,XU Ying,NI Jian,ZHOU Song-wen,XU Jian-fang,LU Mei-jun,WANG Li,CHEN Jie,WANG Zhi
DOI: https://doi.org/10.3781/j.issn.1000-7431.2006.07.007
2006-01-01
Tumor
Abstract:Objective:To investigate the efficacy and safety of intratumoral injection of oncolytic adenovirus H101 in combination with vinorelbine/cispaltin chemotherapy (NP) in patients with advanced non-small cell lung cancer (NSCLC). Methods:The NSCLC patients confirmed by cytological or pathological examination were randomized to receive intratumoral injection of adenovirus H101(1.5×10 12 viral particles) plus NP chemotherapy (Arm A) or only NP chemotherapy (Arm B). Objective response was evaluated every two cycles and time to progression (TTP) and overall survival were followed up. Results:In evaluable 19 patients of Arm A,5 got partial response (PR),10 stable disease (SD),and 4 disease progression (PD), while in evaluable 17 patients of Arm B,3 cases of PR,9 cases of SD,and 5 cases of PD. At the first time of response evaluation,there was 1 case of PD in Arm A,but 5 cases of PD in Arm B. Failure rate in Arm B was significantly higher than that in Arm A(P0.05). Survival curves between the two arms were similar. Six month,9 month and 1 year survival rates were slightly higher and median TTP was also prolonged in Arm A. Except non-infectious fever,other adverse reactions of Arm A were similar to Arm B. There was only 2 patients developing mild pneumothorax in Arm A. Conclusion:Intratumoral injection of H101 viral particles in combination with NP chemotherapy is feasible, effective, and safe in treatment of advanced NSCLC.
What problem does this paper attempt to address?